JP2009005695A5 - - Google Patents

Download PDF

Info

Publication number
JP2009005695A5
JP2009005695A5 JP2008149091A JP2008149091A JP2009005695A5 JP 2009005695 A5 JP2009005695 A5 JP 2009005695A5 JP 2008149091 A JP2008149091 A JP 2008149091A JP 2008149091 A JP2008149091 A JP 2008149091A JP 2009005695 A5 JP2009005695 A5 JP 2009005695A5
Authority
JP
Japan
Prior art keywords
antigen
binding portion
monoclonal antibody
antibody
madcam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008149091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009005695A (ja
JP4729076B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009005695A publication Critical patent/JP2009005695A/ja
Publication of JP2009005695A5 publication Critical patent/JP2009005695A5/ja
Application granted granted Critical
Publication of JP4729076B2 publication Critical patent/JP4729076B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008149091A 2004-01-09 2008-06-06 ＭＡｄＣＡＭに対する抗体 Expired - Lifetime JP4729076B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53549004P 2004-01-09 2004-01-09
US60/535,490 2004-01-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006549399A Division JP4315982B2 (ja) 2004-01-09 2005-01-07 ＭＡｄＣＡＭに対する抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009260786A Division JP5094818B2 (ja) 2004-01-09 2009-11-16 ＭＡｄＣＡＭに対する抗体

Publications (3)

Publication Number Publication Date
JP2009005695A JP2009005695A (ja) 2009-01-15
JP2009005695A5 true JP2009005695A5 (enExample) 2009-04-23
JP4729076B2 JP4729076B2 (ja) 2011-07-20

Family

ID=34794356

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2006549399A Expired - Lifetime JP4315982B2 (ja) 2004-01-09 2005-01-07 ＭＡｄＣＡＭに対する抗体
JP2008149091A Expired - Lifetime JP4729076B2 (ja) 2004-01-09 2008-06-06 ＭＡｄＣＡＭに対する抗体
JP2009260786A Expired - Lifetime JP5094818B2 (ja) 2004-01-09 2009-11-16 ＭＡｄＣＡＭに対する抗体
JP2012154794A Expired - Lifetime JP5836896B2 (ja) 2004-01-09 2012-07-10 ＭＡｄＣＡＭに対する抗体
JP2015138764A Expired - Lifetime JP6215875B2 (ja) 2004-01-09 2015-07-10 ＭＡｄＣＡＭに対する抗体
JP2017004899A Expired - Lifetime JP6423024B2 (ja) 2004-01-09 2017-01-16 ＭＡｄＣＡＭに対する抗体
JP2018087973A Expired - Lifetime JP6637104B2 (ja) 2004-01-09 2018-05-01 ＭＡｄＣＡＭに対する抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006549399A Expired - Lifetime JP4315982B2 (ja) 2004-01-09 2005-01-07 ＭＡｄＣＡＭに対する抗体

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2009260786A Expired - Lifetime JP5094818B2 (ja) 2004-01-09 2009-11-16 ＭＡｄＣＡＭに対する抗体
JP2012154794A Expired - Lifetime JP5836896B2 (ja) 2004-01-09 2012-07-10 ＭＡｄＣＡＭに対する抗体
JP2015138764A Expired - Lifetime JP6215875B2 (ja) 2004-01-09 2015-07-10 ＭＡｄＣＡＭに対する抗体
JP2017004899A Expired - Lifetime JP6423024B2 (ja) 2004-01-09 2017-01-16 ＭＡｄＣＡＭに対する抗体
JP2018087973A Expired - Lifetime JP6637104B2 (ja) 2004-01-09 2018-05-01 ＭＡｄＣＡＭに対する抗体

Country Status (37)

Country Link
US (6) US9328169B2 (enExample)
EP (2) EP2177537B1 (enExample)
JP (7) JP4315982B2 (enExample)
KR (2) KR20120048644A (enExample)
CN (1) CN1956738B (enExample)
AP (1) AP2006003689A0 (enExample)
AR (1) AR047372A1 (enExample)
AT (2) ATE501174T1 (enExample)
AU (1) AU2005204678B2 (enExample)
BR (2) BRPI0506768B1 (enExample)
CA (1) CA2552523C (enExample)
CR (1) CR8485A (enExample)
DE (1) DE602005026779D1 (enExample)
DK (1) DK2177537T3 (enExample)
DO (1) DOP2005000002A (enExample)
EA (1) EA012872B1 (enExample)
EC (1) ECSP066741A (enExample)
ES (2) ES2372733T3 (enExample)
IL (1) IL176749A0 (enExample)
MA (1) MA28430B1 (enExample)
MX (4) MX370489B (enExample)
MY (1) MY140862A (enExample)
NL (1) NL1027975C2 (enExample)
NO (1) NO342054B1 (enExample)
NZ (1) NZ548702A (enExample)
OA (1) OA13358A (enExample)
PA (1) PA8621301A1 (enExample)
PE (1) PE20051053A1 (enExample)
PL (1) PL2177537T3 (enExample)
PT (1) PT2177537E (enExample)
SI (1) SI2177537T1 (enExample)
SV (1) SV2006001990A (enExample)
TN (1) TNSN06216A1 (enExample)
TW (2) TWI363762B (enExample)
UY (1) UY28716A1 (enExample)
WO (1) WO2005067620A2 (enExample)
ZA (1) ZA200605825B (enExample)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2514231A1 (en) * 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies
ES2427641T3 (es) 2003-05-22 2013-10-31 Ibio, Inc. Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
MX370489B (es) * 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
WO2006026759A2 (en) 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
LT2620450T (lt) * 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
ES2351057T3 (es) 2005-07-08 2011-01-31 Pfizer Limited Anticuerpos contra madcam.
BRPI0613459A2 (pt) * 2005-07-11 2011-01-11 Pfizer Ltd combinação de anticorpo anti-madcam e inibidor de caspase antifibrótica para tratar fibrose hepática
WO2007007151A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Use of anti-mad-cam antibody for the treatment of emphysema
WO2007007160A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
CN101378781B (zh) 2005-08-03 2013-08-07 美国弗劳恩霍夫股份有限公司 制造免疫球蛋白的组合物和方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) * 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
US7745584B2 (en) * 2006-05-22 2010-06-29 California Institute Of Technology Antibodies to sulfated carbohydrates
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US20080124272A1 (en) * 2006-09-15 2008-05-29 Vidadi Yusibov Influenza antibodies, compositions, and related methods
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US8404252B2 (en) 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US8912149B1 (en) 2007-11-28 2014-12-16 California Institute Of Technology Glycosaminoglycan mimetics
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
MX2010012368A (es) * 2008-05-16 2010-12-06 Genentech Inc Uso de biomarcadores para evaluar un tratamiento contra trastornos inflamatorios gastrointestinales con antagonistas de beta7-integrina.
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
EP3385279B1 (en) 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
RU2011151069A (ru) 2009-05-15 2013-06-20 Чугаи Сейяку Кабусики Кайся Анти-axl антитело
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US20110158982A1 (en) * 2009-10-05 2011-06-30 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
US20130011406A1 (en) * 2010-03-26 2013-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
CN102603649B (zh) * 2011-01-20 2016-05-25 赣南师范学院 一种以地巴唑为先导分子的荧光探针化合物及其制备方法
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
WO2012145469A1 (en) 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
SG10201912773TA (en) * 2012-08-23 2020-02-27 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
US9273093B2 (en) * 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
BR112015032414A2 (pt) 2013-06-24 2017-11-07 Chugai Pharmaceutical Co Ltd agente terapêutico compreendendo anticorpo antiepirregulina humanizado como ingrediente ativo para carcinoma de pulmão de célula não pequena excluindo adenocarcinoma
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
CA2923145C (en) 2013-09-05 2025-09-16 Amgen Inc. MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
MX377275B (es) 2014-05-16 2025-03-07 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
AU2015258863B2 (en) 2014-05-16 2019-10-24 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
EP3145543A4 (en) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
EP3581585A1 (en) 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
CA2916283C (en) 2015-01-09 2024-07-02 Pfizer Inc. MADCAM ANTAGONIST DOSING REGIMEN
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
SG11201706583PA (en) 2015-02-19 2017-09-28 Compugen Ltd Anti-pvrig antibodies and methods of use
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
CA3017743A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
EP3430053A1 (en) 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
EP3432906A4 (en) 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
EP3433275A1 (en) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
ES3055961T3 (en) 2016-04-28 2026-02-17 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
KR101877349B1 (ko) 2016-08-05 2018-07-17 농업회사법인 주식회사 한라종합식품 황칠 구운 소금 제조방법
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
SG11201901077RA (en) 2016-08-17 2019-03-28 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
JP7165717B2 (ja) * 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
EP3603670A4 (en) 2017-03-31 2021-03-10 Public University Corporation Nara Medical University MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
KR102721137B1 (ko) 2017-05-30 2024-10-25 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
CA3060984A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
US11162943B2 (en) 2017-05-31 2021-11-02 Prometheus Biosciences Inc. Methods for assessing mucosal healing in Crohn's disease patients
AU2018300189B2 (en) * 2017-07-14 2025-05-15 Pfizer, Inc. Antibodies to MAdCAM
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
TW202600611A (zh) 2017-11-01 2026-01-01 日商中外製藥股份有限公司 生物活性降低之抗體變異體與同功型
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
JP2021505156A (ja) * 2017-12-06 2021-02-18 パンディオン・オペレーションズ・インコーポレイテッド 標的化免疫寛容
CN109912715A (zh) 2017-12-13 2019-06-21 凯惠科技发展(上海)有限公司 一种EGFRvIII抗体及其偶联物、制备方法和应用
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
CN119639849A (zh) 2018-03-26 2025-03-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
EP3876986A4 (en) * 2018-09-18 2022-06-01 Pandion Operations, Inc. Targeted immunotolerance
JP2022525754A (ja) * 2019-03-20 2022-05-19 キンドレッド バイオサイエンシズ インコーポレイテッド 医療用ｎｇｆアンタゴニスト
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
MX2022000397A (es) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
CN110887966B (zh) * 2019-12-17 2021-02-12 丹娜(天津)生物科技股份有限公司 一种曲霉菌的化学发光检测试剂盒及其应用
CN118063554A (zh) 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN111714781B (zh) * 2020-06-24 2022-08-05 北京夏禾科技有限公司 一种牙齿美白组合及其使用方法
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
IL309631A (en) * 2021-06-21 2024-02-01 Roussy Inst Gustave Methods for diagnosing cancer- or antibiotic-induced dysbiosis and their use for improving cancer treatment by immunotherapy
TW202330013A (zh) 2021-07-14 2023-08-01 美商健生生物科技公司 介白素－２３受體之脂化肽抑制劑
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
US12112433B2 (en) * 2022-04-06 2024-10-08 Qualcomm Incorporated Apparatus and methods for image reconstruction using machine learning processes
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
EP4623004A1 (en) 2022-11-22 2025-10-01 Takeda Pharmaceutical Company Limited Dosage regimen of madcam-1 antibody for treatment of non-alcoholic steatohepatitis
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5151540A (en) * 1986-11-26 1992-09-29 Hoechst Celanese Corporation Thio carbamates and their derivatives
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US20040010810A1 (en) 1990-01-12 2004-01-15 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
WO1993016043A1 (en) 1992-02-18 1993-08-19 Otsuka Kagaku Kabushiki Kaisha β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
WO1996024673A1 (en) * 1995-02-10 1996-08-15 Leukosite, Inc. Mucosal vascular addressins and uses thereof
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2230759C (en) 1995-08-29 2012-02-21 Kirin Beer Kabushiki Kaisha Chimeric animal and method for producing the same
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US7090845B2 (en) 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
CA2330000C (en) * 1998-05-13 2015-06-23 Genentech, Inc. Diagnosis and treatment of hepatic disorders
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
EP1212407A4 (en) 1999-09-03 2003-04-02 Human Genome Sciences Inc POLYNUCLEOTIDES, POLYPEPTIDES AND ANTIBODIES OF THE IMMUNOGLOBULIN SUPER FAMILY
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
JP2003089656A (ja) * 2001-09-19 2003-03-28 Nippon Kayaku Co Ltd 移植による免疫反応抑制剤
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
SI1485127T1 (sl) 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
US20070202097A1 (en) * 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
WO2005076843A2 (en) 2004-02-06 2005-08-25 Elan Pharmaceuticals, Inc. Methods and compositions for treating tumors and metastatic disease
LT2620450T (lt) 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
ES2351057T3 (es) 2005-07-08 2011-01-31 Pfizer Limited Anticuerpos contra madcam.
CA2613017A1 (en) 2005-07-08 2007-01-18 Pfizer Limited Use of anti-madcam antibodies for the treatment of coeliac disease and tropical sprue
WO2007007151A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Use of anti-mad-cam antibody for the treatment of emphysema
BRPI0613459A2 (pt) 2005-07-11 2011-01-11 Pfizer Ltd combinação de anticorpo anti-madcam e inibidor de caspase antifibrótica para tratar fibrose hepática
WO2007007160A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
WO2007007152A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders

Similar Documents

Publication Publication Date Title
JP2010042025A5 (enExample)
CA2861793C (en) Method of providing monoclonal auto-antibodies with desired specificity
AU2008320987B2 (en) Humanized antibodies against TL1A
CN112262156B (zh) 抗her2抗体
JP2015502145A5 (enExample)
US10875916B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F
JP2022022994A (ja) Ｔｌ１ａ抗体で炎症性腸疾患を処置する方法
CN112513090A (zh) 结合人il-4r的抗体、其抗原结合片段及其医药用途
RU2014120755A (ru) Иммуносвязующие агенты, направленные против tnf
JP2012501670A5 (enExample)
CA2822288A1 (en) Anti-c5/c5a/c5adesr antibodies and fragments
JP6799076B2 (ja) インターフェロンベータ抗体およびその使用
HK1219512A1 (zh) 用於诊断和治疗炎性肠病的方法
JP7851923B2 (ja) インターロイキン１アルファに特異的な真のヒト抗体
TW201127401A (en) Compositions and methods for treating inflammatory disorders
JP2023540444A (ja) 治療用抗体
JP2023518225A5 (enExample)
CA2922937A1 (en) Nav1.7 antibodies and methods of using the same
JP2022521973A5 (enExample)
JP2022529929A (ja) α４β７阻害薬及びＩＬ－２３阻害薬の併用療法
JP2012505227A5 (enExample)
US20230357391A1 (en) Cd47 binding agents and uses thereof
EP4217378A1 (en) Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
JP2020533953A5 (enExample)
US20220267428A1 (en) BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS